What was the outcome of the VANILLA trial for metastatic pancreatic cancer?

The Phase 3 VANILLA trial evaluating aflibercept (VEGF Trap) plus gemcitabine for metastatic pancreatic cancer was discontinued. An Independent Data Monitoring Committee determined that the combination was unlikely to demonstrate a statistically significant improvement in overall survival compared to placebo plus gemcitabine.

What is the significance of completing patient enrollment in the VEGF Trap-Eye Phase 3 trials?

Completing patient enrollment in the two Phase 3 trials for VEGF Trap-Eye in wet age-related macular degeneration (wet AMD) signifies that Regeneron has reached a critical milestone in the development of this drug candidate. This allows the trials to proceed towards their primary endpoints, potentially leading to regulatory submissions and future commercialization in the important ophthalmology market.

How might the discontinuation of the pancreatic cancer trial affect Regeneron's outlook?

The discontinuation of the VANILLA trial represents a setback for Regeneron's oncology program, specifically for aflibercept in the first-line treatment of metastatic pancreatic cancer. Investors will likely monitor the company's strategy and pipeline focus, particularly in light of this negative outcome, while assessing the progress and potential of other aflibercept indications, such as wet AMD.

What is VEGF Trap-Eye and what condition does it aim to treat?

VEGF Trap-Eye, also known as aflibercept, is a drug candidate being evaluated by Regeneron. The Phase 3 trials mentioned in the filing are specifically assessing its efficacy in treating the neovascular form of age-related macular degeneration (wet AMD), a leading cause of vision loss in older adults.

REGN 8-K SEC Disclosure

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on September 14, 2009, reporting two significant clinical trial events. Firstly, the company, in partnership with sanofi-aventis, announced the discontinuation of its Phase 3 VANILLA trial evaluating aflibercept (VEGF Trap) in combination with gemcitabine for metastatic pancreatic cancer. This decision was based on an interim analysis by an Independent Data Monitoring Committee (IDMC) which concluded that the combination would not achieve statistically significant improvement in overall survival compared to placebo plus gemcitabine. Secondly, Regeneron announced the completion of patient enrollment in two Phase 3 clinical trials for VEGF Trap-Eye (aflibercept) in the treatment of wet age-related macular degeneration (wet AMD). This marks a crucial step forward for the development of VEGF Trap-Eye, a key pipeline asset for the company, moving it closer to potential regulatory submissions and commercialization in a significant ophthalmology market.

Key Highlights

1Discontinuation of Phase 3 VANILLA trial for aflibercept in metastatic pancreatic cancer due to lack of expected efficacy.
2Independent Data Monitoring Committee recommended the trial discontinuation based on interim analysis.
3Completion of patient enrollment in two Phase 3 trials for VEGF Trap-Eye in wet age-related macular degeneration (wet AMD).
4VEGF Trap-Eye is being evaluated as a potential treatment for a major ophthalmological condition.
5The filing includes press releases detailing these events as exhibits.
6The pancreatic cancer trial discontinuation suggests a setback in that specific oncology indication for aflibercept.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Sep 14, 2009)

Summary

Key Highlights

Frequently Asked Questions